Power Your Immune-Oncology Projects with Custom Engineered Immune Cells
Gene-editing in immune cell lines can be challenging due to low targeting efficiency and difficulties in single cell derivation of suspension cells. Horizon has validated 10+ immune cell lines including THP-1, Jurkat and NALM-6 cells for gene-editing projects. CRISPR, rAAV and ZFN gene-editing technologies are available depending on project requirements.
Take advantage of the largest panel of pre-characterized immune cell lines available and benefit from Horizon’s exceptional knowhow and experience in completing over 2,000 gene-editing projects.
Request more infocontact usrmation
Gene-Editing for Immuno-Oncology Offering
- Modifications: Knockin, knockout (point mutations, tags and reporter genes)
- Technologies: CRISPR, rAAV or ZFN depending on project requirements
- Project types: Standard or Premium
- Estimated timeline: 13-32 weeks
- Deliverables: Isogenic cell line pair and a summary report
Cell Lines Including
| Cell line | Species | Cell Type | Disease |
| TF-1 | Human | Erythroblast | Erythroleukemia |
| THP-1 | Human | Monocyte | Acute monocytic leukemia |
| MOLT-4 | Human | T-lymphoblast | Acute lymphoblastic leukemia |
| NALM-6 | Human | B-cell | Acute lymphoblastic leukemia |
| KMS-11 | Human | B-cell precursor | Myeloma |
| K-562 | Human | Lymphoblast | Chronic myelogenous leukemia |
| Jurkat | Human | T-lymphocyte | Acute T-cell leukemia |
| J.RT3-T3.5 | Human | T-lymphocyte | Acute T-cell leukemia |
| H9 | Human | Cutaneous T-lymphocyte | Lymphoma |
| CCRF-CEM | Human | T-lymphoblast | Acute lymphoblastic leukemia |
| A20 | Mouse | B-lymphocyte | Reticulum cell sarcoma |
| Case Study I: Heterozygous CRISPR Knockout in Jurkat Cells | |
|
| Positive clone with heterozygous knockout was identified by PCR and Sanger sequencing. An 11 bp deletion introducing a premature stop codon at position 51 exists in one allele. |
| Case Study II: CRISPR-Mediated Gene Disruption in THP-1 Cells | |
|
| Following transfection of THP-1 cells with CRISPR targeting reagents directed against two genes, CRISPR mediated disruption of each gene was identified (indicated by *) by Surveyor assay. |
